Objective To evaluate the potential age- and gender-specific differences in the incidence and prognostic value of coronary artery disease (CAD) in patients undergoing CT coronary angiography (CTA).
Design and patients In this multicentre prospective registry study, 2432 patients (mean age 57±12, 56% male) underwent CTA for suspected CAD. Patients were stratified into four groups according to age <60 or ≥60 years and, male or female gender.
Main outcome measures A composite end point of cardiac death and non-fatal myocardial infarction.
Results CTA results were normal in 991 (41%) patients, showed non-significant CAD in 761 (31%) patients and significant CAD in the remaining 680 (28%) patients. During follow-up (median 819 days, 25–75th centile 482–1142) a cardiovascular event occurred in 59 (2.4%) patients. The annualised event rate was 1.1% in the total population (men=1.3% and women=0.9%). In patients aged <60 years, the annualised event rate of male and female patients was 0.6% and 0.5%, respectively. Among patients aged ≥60 years the annualised event rate was 1.9% in male and 1.1% in female patients. Observations on CTA predicted events in male patients, both age <60 and ≥60 years and in female patients age ≥60 years (log-rank test in all groups, p<0.01). However, CTA provided limited prognostic value in female patients aged <60 years (log-rank test, p=0.45).
Conclusions After age and gender stratification, CTA findings were shown to be of limited predictive value in female patients aged <60 years as compared with male patients at any age and female patients aged ≥60 years.
- CT coronary angiography
- aortic valve disease
- cardiac imaging
- CT scanning
- nuclear cardiology
- lipid drugs
- drug trials
- lipids in atherosclerosis
Statistics from Altmetric.com
Funding KHY receives reseach grants from the Hong Kong Heart Foundation. JWJ receives research grants from and was a speaker at meetings sponsored by Astellas, AstraZeneca, Biotronic, Boston Scientific, Bristol-Myers Squibb, Cordis, Daiichi Sankyo, Eli Lilly and Company, Medtronic, Merck-Schering Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands and the European Community framework KP7 program. JJB receives grants from Biotronik, BMS medical imaging, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medtronic and St Jude Medical. JvW is financially supported by a research grant from the Netherlands Society of Cardiology (Utrecht, The Netherlands). PAK is supported by a grant from the Swiss National Science Foundation (Berne, Switzerland) (SNSF-professorship grant nr.PPOOA-114706), The remaining authors: None.
Competing interests None.
Ethics approval This study was approved by the local ethics committees in all participating centres and all patients provided informed consent.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.